Phase II study of auto-gamma/delta T cell therapy for multiple myeloma.

Phase II study of auto-gamma/delta T cell therapy for multiple myeloma. - Phase II study of auto-gamma/delta T cell therapy for multiple myeloma.

Status

Active, not recruiting

Phases

Phase 2

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000007878

Enrollment

Registered

2012-05-16

Start date

2012-05-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Multiple myeloma

Interventions

Auto-gamma/delta T cells are injected on days 0, 14, 28 and 42.

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Multiple myeloma patients (The patient judged after an induction chemotherapy to be Very good PR or the patient of smoldering multiple myeloma whom free light chain shows an abnormal value) who meet the following: - Age >= 20 years at informed consent. - Performance status is 0-1; - No serious abnormality in bone marrow, liver, and renal functions.

Exclusion criteria

Exclusion criteria: Patients who have: - Uncontrolled infections; - Continuous systemic administration of steroids; - Active autoimmune diseases; - Pregnant, to be pregnant, or nursing mothers; - Active enteritis and/or gastrointestinal bleeding; - Other cancers;

Design outcomes

Primary

Measure	Time frame
Standard value achievement rate	—

Secondary

Measure	Time frame
Time to progression Overall survival Change of serum M protein, serum beta 2-microglobulin, free light chain and Bence Jones protein. Safety	—

Countries

Japan

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026